Combined Phase 3 Double-blind Randomized Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease | NYU Langone Health

Go Back to All Clinical Trials

Combined Phase 3 Double-blind Randomized Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Crohn's Disease
Age: Between 18 years - 75 years
Gender: Male or Female

Other Inclusion Criteria:
1. Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of the screening visit
2. Documented diagnosis of CD with a minimum disease duration of 6 months Moderately to severely active CD

You may not be eligible for this study if the following are true:

1. Current complications of CD such as symptomatic strictures, severe rectal/anal stenosis, fistulae, short bowel syndrome, etc.
2. Use of any prohibited concomitant medications as described in the study protocol that will be reviewed by study staff
3. Participants may be eligible for long term extension treatment (up to 144 weeks)after completion of above protocol